Section Arrow
Quote
ADAP.NASDAQ
- Adaptimmune Therapeutics plc
Quotes are at least 15-min delayed:2024/04/29 19:41 EDT
Last
 1.15
+0.075 (+6.98%)
Day High 
1.2 
Prev. Close
1.075 
1-M High
1.65 
Volume 
1.15M 
Bid
1.15
Ask
1.15
Day Low
1.07 
Open
1.09 
1-M Low
0.8721 
Market Cap 
274.73M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 1.03 
20-SMA 1.19 
50-SMA 1.37 
52-W High 2.05 
52-W Low 0.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.54/-0.88
Enterprise Value
294.58M
Balance Sheet
Book Value Per Share
0.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
60.28M
Operating Revenue Per Share
0.28
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.9898+0.1297+15.08%-- 
JAGXJaguar Health0.208+0.028+15.56%-- 
IBRXImmunityBio8.99+1.64+22.31%-- 
GERNGeron Corp4.14+0.35+9.23%-- 
XFORX4 Pharmaceuticals1.09-0.075-6.44%-- 
Quotes are at least 15-min delayed：2024/04/29 19:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.